Knowledge is increasing about which genetic alterations in which genes are relevant for therapy decisions in different subtypes of adult and paediatric leukaemia.
TLA's unique ability to sequence complete genes and detect all single nucleotide variants and structural variants (including gene fusions) provides important advantages in the analysis and diagnosis of these genes.
The TLA technology can be applied both in the analysis of individual genes of interest and in multiplex analyses.
Examples of the application of multiplex and monoplex TLA analyses in various kinds of leukaemia are provided in the publications cited below.
TLA technology & targeted complete NGS of genes and gene fusions in leukaemia
"Thank you so much. Data about the structural changes in our patient are very clear. Really powerful technology!”Alfredo Brusco Ph.D.(Department of Medical Sciences, University of Turin, Italy)
"Unknown translocation partners that drive expression of oncogenes as consequence of cryptic or previous unidentified chromosomal rearrangements were identified in T-cell leukemia patients using Targeted Locus Amplification.”Jules Meijerink Ph.D.(Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands)
"Targeted Locus Amplification enables fast identification of new chromosomal rearrangements and genomic breakpoint sequences in human T-ALL and unraveled a higher complexity of chromosomal translocations of known T-ALL oncogenes as thus far appreciated.”Pieter van Vlierberghe Ph.D.(Center for Medical Genetics, Ghent University, Belgium)
"We conclude that TLA is an effective method for the reliable detection of sequence mutations and structural variations that are relevant for disease prognosis in pediatric leukemia.”Roland Kuiper Ph.D.(Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands)
- Application notes
Application note on the application of TLA in gene fusion detection in pediatric leukaemia
Application note on MRD testing using TLA data
Alimohamed MZ et al. (2018)
Cergentis & University of Groningen
Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma
Genuardi E et al. (2017)
A.O.U. Citta della Salute e della Scienza di Torino, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Cergentis, Clinica Humanitas/Gavazzeni, University of Modena e Reggio Emilia & University of Torino
Dogliotti I & Ferrero S (2017)
A.O.U. Citta della Salute e della Scienza di Torino & University of Torino
Boer JM et al. (2016)
COALL, DCOG, Erasmus Medical Center, Princess Maxima Center for Pediatric Oncology, Radboud University Medical Center & University of Amsterdam
Splinter E et al. (Poster - 2016)
Cergentis, DCOG, Erasmus Medical Center, Princess Maxima Center for Pediatric Oncology & Radboud University Medical Center
Kuiper RP et al. (2015)
Cergentis, DCOG, Erasmus Medical Center, Radboud University Medical Center
Vroegindeweij EM et al. (2015)
Cergentis, Erasmus Medical Center, Ghent University, KU Leuven & Princess Maxima Center for Pediatric Oncology